In a new study, adding an individualized mRNA-based vaccine to post-surgery pembrolizumab immunotherapy for high-risk melanoma reduced the risk of melanoma recurrence or death by 42% compared with pembrolizumab alone. The findings were announced in a presentation at the ESMO (European Society for Medical Oncology) Congress 2026 in Madrid. According to a press release from the Melanoma Institute Australia, positive results in melanoma suggest this personalized approach may ena